Aprea Therapeutics, Inc. — Form 8-K Summary
Reporting date: June 26, 2020; the report was signed June 30, 2020. The filing covers board changes and results of the 2020 annual meeting of stockholders. No financial statements or operating results were reported.
Business Context and Reporting Period
Aprea Therapeutics, Inc. is a Delaware corporation whose common stock trades on the Nasdaq Global Select Market under the symbol APRE. The company reported director appointments, a director resignation, and stockholder voting outcomes.
Key Financial and Capital Metrics
- Revenue, profit, cash flow, margins, debt, liquidity, and other financial metrics were not provided in this filing.
- No financing, capital-raising, or other balance-sheet transactions were reported.
Material Changes and Corporate Governance
- Fouad Namouni, M.D. was appointed to the Board as a Class II director.
- Richard Peters, M.D., Ph.D. was appointed to the Board as a Class I director. Neither new director was assigned to a board committee at the time of appointment.
- Guido Magni, M.D., Ph.D. resigned from the Board effective June 30, 2020. The resignation was not related to any disagreement with the company regarding operations, policies, or practices.
- The new non-employee directors will receive standard cash compensation and equity compensation described in the company’s April 29, 2020 proxy statement.
Annual Meeting Results, Outlook, and Risks
- Stockholders elected Bernd R. Seizinger, M.D., Ph.D. and Jonathan Hepple, Ph.D. as Class I directors, each to serve until the 2023 annual meeting and until a successor is elected and qualified.
- Votes for Seizinger were 15,759,440, with 3,211,720 votes withheld and 1,371,070 broker non-votes.
- Votes for Hepple were 15,759,201, with 3,211,959 votes withheld and 1,371,070 broker non-votes.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020, with 20,341,993 votes for, 130 against, and 107 abstentions.
- Of 21,054,842 eligible shares, 20,342,230 shares, or approximately 96.6%, were represented at the meeting, constituting a quorum.
- The filing provides no management guidance, operating outlook, material contingencies, or specific risk updates.
Important Facts to Verify
- Confirm the effective date of Guido Magni’s resignation and the board classification and terms of the two newly appointed directors.
- Review the April 29, 2020 proxy statement for the applicable director cash and equity compensation terms.
- Review Exhibit 99.1, described as a June 29, 2020 press release, and reconcile that date with the June 26 report date and June 30 signature date.
- Consult the company’s periodic financial filings for revenue, cash position, liquidity, debt, operating losses, and development-program updates, which are not included here.